GlycoTreat BV is a Dutch biotech company specializing in glycan-based immunotherapy for allergic diseases. Their technology targets cell surface glycans to modulate immune responses by engaging dendritic cells, which helps induce immune tolerance. This approach aims to create more effective and safer allergy treatments by using glycated allergens that enhance antigen presentation and immune regulation, potentially providing long-lasting protection with lower allergen doses. GlycoTreat’s innovative method promotes regulatory T cells while inhibiting harmful immune reactions, even under inflammation.
Nederlands 
English